Drugs / pandemic influenza vaccine (H5N1 strain NIBRG-14)
pandemic influenza vaccine (H5N1 strain NIBRG-14)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00660257 | Jan → Mar 2007 | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00535665 | Sep → Nov 2007 | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pandemic influenza vaccine (H5N1 strain NIBRG-14) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00660257 ↗ |
| Modality | Vaccine | “inactivated pandemic influenza vaccine” NCT00535665 ↗ |
| Route | Intramuscular | “intramuscular injection” NCT00660257 ↗ |